Study of S-1 and Oxaliplatin (SOX) Versus Capecitabine and Oxaliplatin (COX) in Patients With Advanced Colorectal Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

344

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

September 30, 2009

Study Completion Date

January 31, 2011

Conditions
Colorectal Cancer
Interventions
DRUG

S-1 & Oxaliplatin

S-1 and Oxaliplatin : S-1 80 mg/m2/day, D1-14 Oxaliplatin, 130 mg/m2/day, D1 Repeated every 3 weeks

DRUG

Capecitabine & Oxaliplatin

COX : Capecitabine 1000 mg/m2/day, D1-14 Oxaliplatin, 130 mg/m2/day, D1 Repeated every 3 weeks

Trial Locations (11)

410-769

National Cancer Center, Goyang-si

Unknown

Seoul National University Bundang Hospital, Seongnam-si

Gachon University Gil Medical Center, Inchon

Seoul National University Hospital, Seoul

Yonsei University, Seoul

519-809

Chonnam National University Hospital, Hwasun

705-717

Yeungnam University, Daegu

135-710

Samsung Medical Center, Seoul

138-736

Asan Medical Center, Seoul

139-706

Korea Cancer Center Hospital, Seoul

140-743

Soon Chun Hyang University Hospital, Seoul

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

National Cancer Center, Korea

OTHER_GOV

collaborator

Seoul National University Bundang Hospital

OTHER

collaborator

Seoul National University Hospital

OTHER

collaborator

Gachon University Gil Medical Center

OTHER

collaborator

Yonsei University

OTHER

collaborator

Asan Medical Center

OTHER

collaborator

Chonnam National University Hospital

OTHER

lead

Samsung Medical Center

OTHER